Mikael Wallander1, Bo Rolander2,3, Elisabeth Åvall-Lundqvist4,5, Nils O Elander4,5. 1. Department of Oncology, Ryhov County Hospital, SE-55305 Jönköping, Sweden. 2. Futurum - Academy for Healthcare, Region Jönköping County, Sweden. 3. Department of Behavioural Science and Social Work, School of Health and Welfare, Jönköping University, Jönköping, Sweden. 4. Department of Oncology, Linköping University, SE-58185 Linköping, Sweden. 5. Department of Biomedical and Clinical Sciences, Linköping University, SE-58185 Linköping, Sweden.
Abstract
BACKGROUND: While recent randomised phase III trials show that trifluridine/tiperacil (TAS-102) may prolong life in patients with refractory metastatic colorectal cancer (rmCRC), palliative aspects on its efficacy and tolerability in real world patients need further elucidation. METHODS: A retrospective observational multicentre study was designed, including all patients with rmCRC who received TAS-102 under 2016-2019 in the South East Health Care region of Sweden. 48 patients were identified. Primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS), time to ECOG performance status deterioration (PSD), safety and dose reductions, admission to and duration of access to palliative care, and administration of TAS-102 in the last 30 days before death. RESULTS: Median OS, PFS, and time to PSD (a proxy for impaired quality of life) from start of TAS-102 were 6.4 months (95% CI: 4.4-8.4), 2.3 months (95% CI: 1.8-2.7) and 2.5 months (95% CI: 1.9-3.2), respectively. Following uni- and multivariable regression analyses, the number of previous treatment lines (≤2 vs. ≥3) was statistically independent for OS (median 7.8 vs. 5.3 months, P=0.05), PFS (median 2.4 vs. 1.8 months, P=0.03), and time to PSD (median 2.8 vs. 1.8 months, P=0.03). Thirty-four (71%) of the patients received reduced doses. The most common grade 3-4 toxicity was neutropenia (39%). Forty-three (90%) were admitted to GP or hospital-based home palliative care. Median time for access to any form of palliative care before death was 2.3 (95% CI: 0.5-3.2) months. Few patients (n=3, 7%) received their last dose of TAS-102 in their last 30 days of life. CONCLUSIONS: The outcome and tolerability of TAS-102 in rmCRC appear similar in a real-world context and randomised trials. The retrospective design and limited sample size preclude firm conclusions on subgroup analyses, but it appears that the prognosis is slightly better the earlier TAS-102 is introduced. Treatment durations are generally short, and early admission to a palliative care provider is recommended. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: While recent randomised phase III trials show that trifluridine/tiperacil (TAS-102) may prolong life in patients with refractory metastatic colorectal cancer (rmCRC), palliative aspects on its efficacy and tolerability in real world patients need further elucidation. METHODS: A retrospective observational multicentre study was designed, including all patients with rmCRC who received TAS-102 under 2016-2019 in the South East Health Care region of Sweden. 48 patients were identified. Primary outcome was overall survival (OS) and secondary outcomes were progression-free survival (PFS), time to ECOG performance status deterioration (PSD), safety and dose reductions, admission to and duration of access to palliative care, and administration of TAS-102 in the last 30 days before death. RESULTS: Median OS, PFS, and time to PSD (a proxy for impaired quality of life) from start of TAS-102 were 6.4 months (95% CI: 4.4-8.4), 2.3 months (95% CI: 1.8-2.7) and 2.5 months (95% CI: 1.9-3.2), respectively. Following uni- and multivariable regression analyses, the number of previous treatment lines (≤2 vs. ≥3) was statistically independent for OS (median 7.8 vs. 5.3 months, P=0.05), PFS (median 2.4 vs. 1.8 months, P=0.03), and time to PSD (median 2.8 vs. 1.8 months, P=0.03). Thirty-four (71%) of the patients received reduced doses. The most common grade 3-4 toxicity was neutropenia (39%). Forty-three (90%) were admitted to GP or hospital-based home palliative care. Median time for access to any form of palliative care before death was 2.3 (95% CI: 0.5-3.2) months. Few patients (n=3, 7%) received their last dose of TAS-102 in their last 30 days of life. CONCLUSIONS: The outcome and tolerability of TAS-102 in rmCRC appear similar in a real-world context and randomised trials. The retrospective design and limited sample size preclude firm conclusions on subgroup analyses, but it appears that the prognosis is slightly better the earlier TAS-102 is introduced. Treatment durations are generally short, and early admission to a palliative care provider is recommended. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Trifluridine and tiperacil (TAS-102); chemotherapy; colorectal neoplasms; palliative care
Authors: Stig E Andersen; Ida B Andersen; Benny V Jensen; Per Pfeiffer; Takayo Ota; Jim S Larsen Journal: Acta Oncol Date: 2019-04-19 Impact factor: 4.089
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Pashtoon M Kasi; Daisuke Kotani; Michael Cecchini; Kohei Shitara; Atsushi Ohtsu; Ramesh K Ramanathan; Howard S Hochster; Axel Grothey; Takayuki Yoshino Journal: BMC Cancer Date: 2016-07-13 Impact factor: 4.430
Authors: Johannes J M Kwakman; G Vink; J H Vestjens; L V Beerepoot; J W de Groot; R L Jansen; F L Opdam; H Boot; G J Creemers; J M van Rooijen; M Los; A J E Vulink; H Schut; E van Meerten; A Baars; P Hamberg; E Kapiteijn; D W Sommeijer; C J A Punt; M Koopman Journal: Int J Clin Oncol Date: 2017-12-04 Impact factor: 3.402